Efficacy of acupuncture and moxibustion in adjuvant treatment of patients with novel coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis

• Published in: Medicine (Baltimore) Vol. 99; no. 28; p. e21039
• Main Authors: Zhang, Qiongshuai, Xu, Xiaohong, Sun, Shaoqian, Cao, Fang, Li, Jiannan, Qi, Xun, Ji, Guangcheng, Wang, Yufeng, Song, Bailin
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 10.07.2020
• Subjects: Acupuncture Therapy - methods; Betacoronavirus - isolation & purification; Combined Modality Therapy - methods; Coronavirus Infections - drug therapy; Coronavirus Infections - therapy; COVID-19; Humans; Meta-Analysis as Topic; Moxibustion - methods; Pandemics; Pneumonia, Viral - therapy; Research Design; SARS-CoV-2; Study Protocol Systematic Review; Systematic Reviews as Topic; Treatment Outcome
• DOI: 10.1097/MD.0000000000021039
• ISSN: 0025-7974

Novel coronavirus has infected 4.33 million people in more than 200 countries in the current global outbreak of COVID-19. However, there is still no effective drug to treat the disease, and acupuncture and moxibustion is utilized as adjuvant therapy for the treatment of COVID-19 in China. Nine electronic databases: PubMed, EMBASE, Cochrane library, Web of Science (WOS), Google Scholar, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wan Fang database (Wanfang) and 2 clinical trials register platforms: Chinese Clinical Trial Registry (ChiCTR), ClinicalTrials.gov (www.ClinicalTrials.gov/) will be searched for RCTs of A&M for COVID-19. The screening process will be developed by 2 independent reviewers, and meta-analysis will be performed with RevMan (V5.3.5) software. The study results will be contributed to a scientific journal after peer-reviewed for publication. The study will provide up-to-date evidence of the effectiveness and safety of A&M for patients with COVID-19. CRD42020185776.